Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation Journal Article


Authors: Dotsu, Y.; Fukuda, M.; Honda, N.; Gyotoku, H.; Kohno, Y.; Suyama, T.; Umeyama, Y.; Taniguchi, H.; Takemoto, S.; Yamaguchi, H.; Miyazaki, T.; Sakamoto, N.; Obase, Y.; Ikeda, H.; Ashizawa, K.; Mukae, H.
Article Title: Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation
Abstract: Dabrafenib and trametinib therapy for BRAF V600E-mutant non-small cell lung cancer (NSCLC) has demonstrated strong antitumor effects in clinical trials and has been approved for use in clinical practice. However, the efficacy and safety of this combination therapy in elderly patients remain unclear. An 86-year-old male patient, who had been diagnosed with lung adenocarcinoma with the BRAF V600E mutation, received dabrafenib and trametinib combination chemotherapy. The tumor shrunk rapidly; however, therapy was discontinued after 40 days because adverse events (hypoalbuminemia, peripheral edema, and pneumonia) developed. Although this targeted combination therapy seemed to cause relatively severe adverse events compared with single-agent targeted therapy in this “oldest old” elderly patient, the marked tumor shrinkage prolonged the patient's life and helped him to maintain a good general condition. Active targeted therapy may therefore be considered with appropriate drug dose reduction instead of conservative treatment, even if a patient is extremely old. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Keywords: elderly; non-small cell lung cancer; dabrafenib; trametinib; braf v600e
Journal Title: Thoracic Cancer
Volume: 12
Issue: 2
ISSN: 1759-7706
Publisher: Wiley-Blackwell Publishing Asia  
Date Published: 2021-01-01
Start Page: 272
End Page: 276
Language: English
DOI: 10.1111/1759-7714.13756
PUBMED: 33215864
PROVIDER: scopus
PMCID: PMC7812073
DOI/URL:
Notes: Article -- Export Date: 1 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors